Madrigal Pharmaceuticals
MDGL
Performance
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Its research aims to halt or reverse liver fibrosis and treat MASH to prevent progression to cirrhosis, liver failure, or transplantation. The company highlights FDA-approved treatment in MASH and communicates a commitment to advancing care for patients affected by lipid-related liver disorders. Headquartered in the United States, Madrigal emphasizes science-driven innovation and leadership in hepatology research.
Recent News
STAT+: Novo Nordisk’s Less-Bad News on Its Wegovy Pill Boosts Earnings and Share Price
Madrigal Eyes Combination MASH Therapy with Pfizer Deal
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
Hepatitis Vaccine Uptake Declining, Liver Disease Could Increase
MASH Care Demands More Than New Drugs: Meena Bansal, MD
Madrigal Pharmaceuticals Inc (MDGL) Q1 2026 Earnings Call Transcript
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
After Early Semaglutide Lead, Torrent Pharma Eyes US Liver Drug Resmetirom for India Launch
MASH Cirrhosis Trials Lack Consistent End Points
UCB Bags First EU Approval for Rare Genetic Disease TK2d